CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...

When Vijay Sankaran was an MD-PhD student at Harvard Medical School in the mid-2000s, one of his first clinical encounters ...

Esther Nkemakolam runs her fingers through kinetic sand and sings a “Moana” song as UPMC Children’s Hospital nurse Taylor ...

There is huge unmet need for new rare disease therapies, where patients have few or no available options. According to the ...

The stock, which has tumbled more than 45% over the past year, could climb 87% within the coming 12 months, Wall Street ...

The sickle cell treatments available before Casgevy focused on symptom management such as reducing the frequency of ...

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the ...

Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.

Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to ...

In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...